mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
DRUG: Fluorouracil|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Paclitaxel|DRUG: calcium levofolinate
Progression-Free Survival (PFS), 24 months|Adverse Event（AE）, NCI CTC 4.03, 35 months
Objective Response Rate (ORR), 24 months|Disease Control Rate (DCR), 24 months|Overall Survival (OS), 35 months|Quality of Life (QoL), Use the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 \[EORTC QLQ-C30\]., 35 months
In previous studies, we found that mFOLFOX(a Combination of Oxaliplatin, Fluorouracil), mFOLFIRI(a Combination of Irinotecan, Fluorouracil), FOLFPTX (a Combination of Paclitaxel, Fluorouracil) are active in patients with AGC or EGJA.This study is being done to find out which one has the best efficacy.